Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor

References

• Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG. (2008). Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase ½ inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139–2146.
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–227.
   PubMedGoogle Scholar
• Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254.
   PubMed Web of Science ®Google Scholar
• Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Trocóniz IF. (2008). Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 44:142–150.
   PubMed Web of Science ®Google Scholar
• Daouti S, Higgins B, Kolinsky K, Packman K, Wang H, Rizzo C, Moliterni J, Huby N, Fotouhi N, Liu M, Goelzer P, Sandhu HK, Li JK, Railkar A, Heimbrook D, Niu H. (2010). Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models. Mol Cancer Ther 9:134–144.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• Downward J. (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11–22.
   PubMed Web of Science ®Google Scholar
• Dunnett C. (1955). A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50:1096–1121.
   Web of Science ®Google Scholar
• Friday BB, Adjei AA. (2008). Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14:342–346.
   PubMed Web of Science ®Google Scholar
• Huang CY, Ferrell JE Jr. (1996). Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 93:10078–10083.
   PubMed Web of Science ®Google Scholar
• Jang SH, Wientjes MG, Lu D, Au JL. (2003). Drug delivery and transport to solid tumors. Pharm Res 20:1337–1350.
   PubMed Web of Science ®Google Scholar
• Kelland LR. (2004). Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40:827–836.
   PubMed Web of Science ®Google Scholar
• Lee L, Niu H, Rueger R, Igawa Y, Deutsch J, Ishii N, Mu S, Sakamoto Y, Busse-Reid R, Gimmi C, Goelzer P, De Schepper S, Yoshimura Y, Barrett J, Ishikawa Y, Weissgerber G, Peck R. (2009). The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker. Clin Cancer Res 15:7368–7374.
   Google Scholar
• Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:5281–5293.
   PubMed Web of Science ®Google Scholar
• Mager DE, Woo S, Jusko WJ. (2009). Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24:16–24.
   PubMed Web of Science ®Google Scholar
• Mager DE, Wyska E, Jusko WJ. (2003). Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510–518.
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2005). Interspecies Pharmacokinetic Scaling. Rockville, Maryland: Pine House Publishers.
   Google Scholar
• Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–895.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. (2007). Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263–1284.
   PubMed Web of Science ®Google Scholar
• Rocchetti M, Del Bene F, Germani M, Fiorentini F, Poggesi I, Pesenti E, Magni P, De Nicolao G. (2009). Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach. Eur J Cancer 45:3336–3346.
   PubMed Web of Science ®Google Scholar
• Rowland M, Tozer TN. (1995). Clinical Pharmacokinetics: concepts and applications. Philadelphia: Lippincott Williams & Wilkins.
   Google Scholar
• Sausville EA, Burger AM. (2006). Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66:3351–4, discussion 3354.
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS, Herrera R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937–947.
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358–362.
   PubMed Web of Science ®Google Scholar
• Tanaka C, O’Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA. (2008). Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596–1602.
   PubMedGoogle Scholar
• Teicher BA. (2006). Tumor models for efficacy determination. Mol Cancer Ther 5:2435–2443.
   PubMed Web of Science ®Google Scholar
• Wang S, Guo P, Wang X, Zhou Q, Gallo JM. (2008). Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther 7:407–417.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhou Q, Gallo JM. (2009). Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther 8:1438–1447.
   PubMed Web of Science ®Google Scholar
• Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, Choo EF. (2009). Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1 H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther 329:360–367.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, Koudriakova T. (2008). Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36:1267–1274.
   PubMed Web of Science ®Google Scholar